Brandon Essink

3.7k total citations · 2 hit papers
37 papers, 1.1k citations indexed

About

Brandon Essink is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Brandon Essink has authored 37 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 23 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Brandon Essink's work include Respiratory viral infections research (16 papers), SARS-CoV-2 and COVID-19 Research (13 papers) and Viral gastroenteritis research and epidemiology (7 papers). Brandon Essink is often cited by papers focused on Respiratory viral infections research (16 papers), SARS-CoV-2 and COVID-19 Research (13 papers) and Viral gastroenteritis research and epidemiology (7 papers). Brandon Essink collaborates with scholars based in United States, Netherlands and France. Brandon Essink's co-authors include Bethany Girard, Rituparna Das, Lindsey R. Baden, Jacqueline M. Miller, Jing Feng, Spyros Chalkias, Haiyu Zhou, Darin K. Edwards, David C. Montefiori and Ying Chang and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Brandon Essink

32 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

2022 346 citations Spyros Chalkias, Charles Harper et al. profile →
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

2023 97 citations Brandon Essink, Laurence Chu et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brandon Essink United States	15	622	397	225	158	119	37	1.1k
Thanunrat Thongmee Thailand	18	550 0.9×	278 0.7×	73 0.3×	65 0.4×	106 0.9×	54	836
Laurence Chu United States	13	391 0.6×	255 0.6×	143 0.6×	109 0.7×	57 0.5×	22	656
Annelies W. Mesman United States	15	395 0.6×	452 1.1×	137 0.6×	302 1.9×	44 0.4×	24	873
Victor H. Ferreira Canada	20	546 0.9×	437 1.1×	127 0.6×	367 2.3×	52 0.4×	59	1.3k
Hoe Nam Leong Singapore	16	839 1.3×	660 1.7×	157 0.7×	155 1.0×	32 0.3×	23	1.5k
Alessandro Manenti Italy	14	682 1.1×	202 0.5×	165 0.7×	103 0.7×	41 0.3×	46	933
Karoline Bragstad Norway	19	508 0.8×	649 1.6×	129 0.6×	107 0.7×	57 0.5×	51	1.0k
Serena Marchi Italy	17	417 0.7×	428 1.1×	134 0.6×	107 0.7×	43 0.4×	63	1.0k
Jeff Connell Ireland	20	434 0.7×	790 2.0×	83 0.4×	70 0.4×	116 1.0×	67	1.1k
Shirin Strohmeier United States	21	1.5k 2.4×	757 1.9×	328 1.5×	525 3.3×	91 0.8×	44	2.3k

Countries citing papers authored by Brandon Essink

Since Specialization

Citations

This map shows the geographic impact of Brandon Essink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon Essink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon Essink more than expected).

Fields of papers citing papers by Brandon Essink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon Essink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon Essink. The network helps show where Brandon Essink may publish in the future.

Co-authorship network of co-authors of Brandon Essink

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon Essink. A scholar is included among the top collaborators of Brandon Essink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon Essink. Brandon Essink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miyake‐Stoner, Shigeki J., Brandon Essink, Jessica L. Sparks, et al.. (2025). Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial. Communications Medicine. 5(1). 392–392.

Deming, Meagan E., Elizabeth R. Brown, Monica A. McArthur, et al.. (2025). Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial. The Lancet Microbe. 6(4). 100984–100984. 2 indexed citations

Essink, Brandon, et al.. (2025). A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine. 51. 126791–126791.

Folegatti, Pedro M., Stéphanie Pépin, Katherine Fries, et al.. (2025). Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study. The Lancet Infectious Diseases. 25(10). 1097–1105. 2 indexed citations

Priddy, Frances, Spyros Chalkias, Brandon Essink, et al.. (2024). A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children. Expert Review of Vaccines. 23(1). 862–878. 6 indexed citations

Shaw, Christine A., Brandon Essink, Charles Harper, et al.. (2024). Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults. The Journal of Infectious Diseases. 230(3). e647–e656. 36 indexed citations

Tricou, Vianney, Brandon Essink, John Ervin, et al.. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS neglected tropical diseases. 17(3). e0011124–e0011124. 16 indexed citations

Follmann, Dean, Xiaowei Wang, Peter B. Gilbert, et al.. (2023). 1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves. Open Forum Infectious Diseases. 10(Supplement_2).

Chalkias, Spyros, Charles Harper, Keith Vrbicky, et al.. (2023). Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19. Nature Communications. 14(1). 5125–5125. 11 indexed citations

10.

Essink, Brandon, Laurence Chu, Elizabeth Barranco, et al.. (2023). The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. The Lancet Infectious Diseases. 23(5). 621–633. 97 indexed citations breakdown →

11.

Chalkias, Spyros, Frank Eder, Brandon Essink, et al.. (2022). Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nature Medicine. 28(11). 2388–2397. 70 indexed citations

12.

Peterson, James T., Agnieszka Zareba, David Fitzpatrick, et al.. (2021). Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. The Journal of Infectious Diseases. 225(12). 2077–2086. 31 indexed citations

13.

Essink, Brandon, James T. Peterson, Kari Yacisin, et al.. (2021). A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. Human Vaccines & Immunotherapeutics. 17(8). 2691–2699. 2 indexed citations

14.

Essink, Brandon, Charu Sabharwal, Xia Xu, et al.. (2020). 3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older. Open Forum Infectious Diseases. 7(Supplement_1). S2–S2. 10 indexed citations

15.

Klein, Nicola P., et al.. (2019). Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine. 37(32). 4460–4467. 5 indexed citations

16.

Essink, Brandon, Carlos Fierro, Jeffrey B. Rosen, et al.. (2019). Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 38(2). 242–250. 28 indexed citations

17.

Welsch, Jo Anne, Shelly Senders, Brandon Essink, et al.. (2018). Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study. Vaccine. 36(35). 5309–5317. 23 indexed citations

18.

Treanor, John J., Laurence Chu, Brandon Essink, et al.. (2017). Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 35(6). 923–928. 9 indexed citations

19.

Johnston, William, Brandon Essink, Judith L. Kirstein, et al.. (2015). Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2–10 Years of Age. The Pediatric Infectious Disease Journal. 35(1). e19–e27. 7 indexed citations

20.

Treanor, John J., Brandon Essink, Steven Hull, et al.. (2013). Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine. 31(48). 5760–5765. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact